News Releases

Zelda Therapeutics to Webcast, Live, at January 18

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual

PERTH, Australia, Jan. 12, 2018 /PRNewswire/ -- Zelda Therapeutics (ASX: ZLD), based in Australia, focused on medical cannabis therapies today announced that Dr. Stewart Washer, Executive Director, will present live at on January 18.

View investor presentations 24/7 at . (PRNewsFoto/OTC Markets Group Inc.)

DATE: Thursday, January 18, 2018
TIME: 9:30 AM ET

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Learn more about the event at

Recent Company Highlights

  • In December 2017 Zelda Therapeutics announced its collaboration with the Children's Hospital of Philadelphia for an observational study of cannabinoids on autism.
  • Recently received Australia's first regulatory approval to conduct a medicinal cannabis trial to treat chronic insomnia.
  • Zelda has shown a positive effect with their cannabis extracts on human breast cancer cell lines
  • Zelda is now studying cannabis extracts on pancreatic and brain cancer cell lines

About Zelda Therapeutics

Zelda Therapeutics Limited ("Zelda") is an Australian biotechnology company which listed on the Australian Stock Exchange (ASX) in 2016, trading under the ASX code "ZLD". The company is developing medicinal cannabis therapies in collaboration with a number of key international leaders and research organisations. Zelda has exclusive access to comprehensive patient data that has demonstrated therapeutic success using cannabinoid-based treatments and has leveraged this to commence pre-clinical research in breast, brain and pancreatic cancer and will commence human clinical trials in 2018 on a number of other disorders including insomnia and autism.

Since 2010,, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.


SOURCE Zelda Therapeutics

For further information: Zelda Therapeutics- Stewart Washer, Executive Director, +61 418 288 212,; John Viglotti, VP, Investor Relations Products and Services, Cision / PR Newswire / MultiVu, +1.201.360.6767,